Eli Lilly stock has been a big-time winner ... retaliatory tariffs from other countries could also weigh on Lilly's business; the company could start to see diminished brand equity in ...

Eli Lilly said in February that it will invest at least $27 billion to build four new manufacturing sites in the U.S. as demand for its weight loss and diabetes injections soars and the company ...

From late 2020 to the summer of 2024, Eli Lilly & Co ... Billions Since 2016, Lilly’s revenue grew by 60% but income grew by 91%. Typically, you would not expect a company growing at its ...

Eli Lilly and Co., the maker of Zepbound and Mounjaro, announced success Thursday of its Phase 3 clinical trial for a once-daily GLP-1 pill — an oral form of the blockbuster medication used for ...

Shares in Chugai Pharmaceutical, the Japanese company that invented the drug and licensed it to Eli Lilly in 2018, soared to a record high on Friday in Tokyo, jumping 16 per cent higher on the ...

Lilly's already holding its own in immunology with Taltz, which made nearly $3.3 billion in sales last year. Omvoh could carve a niche for itself in the Crohn's disease market. Ebglyss should also ...

In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against other other firms that ended the week strong. The stock market ended the shortened trading ...

We recently published a list of 10 Firms End Stronger, Buck Muted Broader Market Trading. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against other ...

Eli Lilly and Company, which already markets weight-loss and diabetes drugs that must be injected, is a step closer to introducing a once-daily pill for the same conditions. On April 17 ...

The company expects those regulatory filings to come by the end of the year for obesity and in 2026 for diabetes. What it means: Current GLP-1 drugs used for weight loss, including Eli Lilly's ...